Filing Flows › Senseonics Holdings (SENS) › Guidance & outlook

Senseonics Holdings (SENS) guidance and outlook

Senseonics Holdings' 10-Q filed Nov 9, 2026 makes 16 forward-looking statements.

Guidance and outlook

Forward-looking statements, 10-Q filed Nov 9, 2026

• customers had transitioned to Eversense 365, and we expect the remaining customers to transition over the coming months.
• We leverage and target regions where we have coverage decisions for patient device use and provider insertion and removal procedure payment.
• In both the United States and our overseas markets we will commercialize the products with direct sales forces and distribution systems that market and promote our various Eversense Systems and future generation products, including our Gemini and Freedom product variations.
• We have increased our target for the Eon Care network to 120 inserters by the end of 2026.
• We currently plan to complete the pivotal study during the first half of 2027, with a 510(k) submission following its completion.
• Data gathered from this first-in-human testing is expected to inform a planned pivotal study, which we expect to initiate in 2027.
• As of September 30, 2026, the substantial majority of our European customers had transitioned to Eversense 365, and we expect the remaining customers to transition over the coming months.
• Revenue from product sales to Ascensia is recognized at a point in time when Ascensia obtains control of our product based upon the delivery terms as defined in the contract at an amount that reflects the consideration which we expect to receive in exchange for the product.
• The consideration we expect to receive includes estimates of variable consideration for which reserves are established, primarily arising from patient assistance program rebates, prompt-pay discounts, tier-volume price discounts and, prior to January 1, 2026, revenue share in connection with the Commercialization Agreement.
• Depending on the variable consideration, we develop estimates for the expected value based on the terms of the agreements, historical data, geographic mix, reimbursement rates, and market conditions.
• This increase was primarily driven by the ramp up of our Gemini clinical study which adds an implantable battery to power the sensor, as well as higher salary, contract fabrication, and consulting costs in support of additional product development projects to advance our Freedom product to eliminate the on-body transmitter component.
• This increase was primarily driven by the ramp up of our Gemini clinical study driving efforts to enable a self-powered battery enabled sensor and additional product development projects, as well as higher salary, contract fabrication, and consulting costs in support of additional product development projects to progress our freedom product to eliminate the on-body transmitter component.

Senseonics Holdings' latest quarter

Questions

What does Senseonics Holdings expect?

customers had transitioned to Eversense 365, and we expect the remaining customers to transition over the coming months. We leverage and target regions where we have coverage decisions for patient device use and provider insertion and removal procedure payment. In both the United States and our overseas markets we will commercialize the products with direct sales forces and distribution systems that market and promote our various Eversense Systems and future generation products, including our Gemini and Freedom product variations.

Open the interactive view →

Updated Nov 9, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.